168 related articles for article (PubMed ID: 29080252)
1. Clinical Evaluation of Tavocept to Decrease Diuresis Time and Volume in Dogs with Bladder Cancer Receiving Cisplatin.
Henry CJ; Flesner BK; Bechtel SA; Bryan JN; Tate DJ; Selting KA; Lattimer JC; Bryan ME; Grubb L; Hausheer F
J Vet Intern Med; 2018 Jan; 32(1):370-376. PubMed ID: 29080252
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of cisplatin administered with piroxicam in dogs with transitional cell carcinoma of the urinary bladder.
Greene SN; Lucroy MD; Greenberg CB; Bonney PL; Knapp DW
J Am Vet Med Assoc; 2007 Oct; 231(7):1056-60. PubMed ID: 17916030
[TBL] [Abstract][Full Text] [Related]
3. Cisplatin treatment of transitional cell carcinoma of the urinary bladder in dogs: 18 cases (1983-1993).
Chun R; Knapp DW; Widmer WR; Glickman NW; DeNicola DB; Bonney PL
J Am Vet Med Assoc; 1996 Nov; 209(9):1588-91. PubMed ID: 8899023
[TBL] [Abstract][Full Text] [Related]
4. Piroxicam, mitoxantrone, and coarse fraction radiotherapy for the treatment of transitional cell carcinoma of the bladder in 10 dogs: a pilot study.
Poirier VJ; Forrest LJ; Adams WM; Vail DM
J Am Anim Hosp Assoc; 2004; 40(2):131-6. PubMed ID: 15007049
[TBL] [Abstract][Full Text] [Related]
5. Randomized trial of cisplatin versus firocoxib versus cisplatin/firocoxib in dogs with transitional cell carcinoma of the urinary bladder.
Knapp DW; Henry CJ; Widmer WR; Tan KM; Moore GE; Ramos-Vara JA; Lucroy MD; Greenberg CB; Greene SN; Abbo AH; Hanson PD; Alva R; Bonney PL
J Vet Intern Med; 2013; 27(1):126-33. PubMed ID: 23205923
[TBL] [Abstract][Full Text] [Related]
6. Effects of the cyclooxygenase inhibitor, piroxicam, in combination with chemotherapy on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer.
Mohammed SI; Craig BA; Mutsaers AJ; Glickman NW; Snyder PW; deGortari AE; Schlittler DL; Coffman KT; Bonney PL; Knapp DW
Mol Cancer Ther; 2003 Feb; 2(2):183-8. PubMed ID: 12589035
[TBL] [Abstract][Full Text] [Related]
7. Cisplatin versus cisplatin combined with piroxicam in a canine model of human invasive urinary bladder cancer.
Knapp DW; Glickman NW; Widmer WR; DeNicola DB; Adams LG; Kuczek T; Bonney PL; DeGortari AE; Han C; Glickman LT
Cancer Chemother Pharmacol; 2000; 46(3):221-6. PubMed ID: 11021739
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of carbon dioxide laser ablation combined with mitoxantrone and piroxicam treatment in dogs with transitional cell carcinoma.
Upton ML; Tangner CH; Payton ME
J Am Vet Med Assoc; 2006 Feb; 228(4):549-52. PubMed ID: 16478428
[TBL] [Abstract][Full Text] [Related]
9. Retrospective evaluation of doxorubicin-piroxicam combination for the treatment of transitional cell carcinoma in dogs.
Robat C; Burton J; Thamm D; Vail D
J Small Anim Pract; 2013 Feb; 54(2):67-74. PubMed ID: 23286739
[TBL] [Abstract][Full Text] [Related]
10. Cisplatin (cisdiamminedichloroplatinum) for treatment of transitional cell carcinoma of the urinary bladder or urethra. A retrospective study of 15 dogs.
Moore AS; Cardona A; Shapiro W; Madewell BR
J Vet Intern Med; 1990; 4(3):148-52. PubMed ID: 2366224
[TBL] [Abstract][Full Text] [Related]
11. Piroxicam therapy in 34 dogs with transitional cell carcinoma of the urinary bladder.
Knapp DW; Richardson RC; Chan TC; Bottoms GD; Widmer WR; DeNicola DB; Teclaw R; Bonney PL; Kuczek T
J Vet Intern Med; 1994; 8(4):273-8. PubMed ID: 7983623
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of cisplatin combined with piroxicam for the treatment of oral malignant melanoma and oral squamous cell carcinoma in dogs.
Boria PA; Murry DJ; Bennett PF; Glickman NW; Snyder PW; Merkel BL; Schlittler DL; Mutsaers AJ; Thomas RM; Knapp DW
J Am Vet Med Assoc; 2004 Feb; 224(3):388-94. PubMed ID: 14765798
[TBL] [Abstract][Full Text] [Related]
13. Clinical outcome of partial cystectomy for transitional cell carcinoma of the canine bladder.
Marvel SJ; Séguin B; Dailey DD; Thamm DH
Vet Comp Oncol; 2017 Dec; 15(4):1417-1427. PubMed ID: 28217972
[TBL] [Abstract][Full Text] [Related]
14. Toxic effects and antitumor response of gemcitabine in combination with piroxicam treatment in dogs with transitional cell carcinoma of the urinary bladder.
Marconato L; Zini E; Lindner D; Suslak-Brown L; Nelson V; Jeglum AK
J Am Vet Med Assoc; 2011 Apr; 238(8):1004-10. PubMed ID: 21492043
[TBL] [Abstract][Full Text] [Related]
15. Piroxicam for bladder cancer.
Barsanti JA
J Vet Intern Med; 1995; 9(2):113-4. PubMed ID: 7760310
[No Abstract] [Full Text] [Related]
16. Randomized phase III trial of piroxicam in combination with mitoxantrone or carboplatin for first-line treatment of urogenital tract transitional cell carcinoma in dogs.
Allstadt SD; Rodriguez CO; Boostrom B; Rebhun RB; Skorupski KA
J Vet Intern Med; 2015 Jan; 29(1):261-7. PubMed ID: 25619518
[TBL] [Abstract][Full Text] [Related]
17. Antitumor effects of deracoxib treatment in 26 dogs with transitional cell carcinoma of the urinary bladder.
McMillan SK; Boria P; Moore GE; Widmer WR; Bonney PL; Knapp DW
J Am Vet Med Assoc; 2011 Oct; 239(8):1084-9. PubMed ID: 21985349
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of nephrotoxicosis associated with a short-term saline solution diuresis protocol for the administration of cisplatin to dogs with malignant tumors: 61 cases (1987-1989).
Ogilvie GK; Straw RC; Powers BE; Cooper MF; Withrow SJ
J Am Vet Med Assoc; 1991 Sep; 199(5):613-6. PubMed ID: 1787122
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of nephrotoxicosis associated with a four-hour saline solution diuresis protocol for the administration of cisplatin to dogs with naturally developing neoplasms.
Ogilvie GK; Straw RC; Jameson VJ; Walters LM; Lafferty M; Powers BE; Henkel SE; Withrow SJ
J Am Vet Med Assoc; 1993 Jun; 202(11):1845-8. PubMed ID: 8320153
[TBL] [Abstract][Full Text] [Related]
20. Clinical evaluation of mitoxantrone and piroxicam in a canine model of human invasive urinary bladder carcinoma.
Henry CJ; McCaw DL; Turnquist SE; Tyler JW; Bravo L; Sheafor S; Straw RC; Dernell WS; Madewell BR; Jorgensen L; Scott MA; Higginbotham ML; Chun R
Clin Cancer Res; 2003 Feb; 9(2):906-11. PubMed ID: 12576466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
